5-fluorouracil + doxorubicin + cisplatin + mitomycin C + thiotepa

This is a combination chemotherapy regimen consisting of five antineoplastic agents. Each drug has a distinct mechanism of action, and the combination is used to target cancer cells through multiple pathways, potentially increasing efficacy and overcoming resistance. The regimen has been studied in clinical trials for advanced cancers such as non-small cell lung cancer and bladder cancer, but its use is not standard due to limited efficacy and significant toxicity[1][4]. The main toxicities include myelosuppression (low blood cell counts), nausea, vomiting, renal toxicity (from cisplatin), cardiotoxicity (from doxorubicin), and other organ-specific side effects[1][5].